Loss of phospholipid asymmetry in human platelet plasma membrane after 1-12 days of storage. An ESR study.
We used paramagnetic analogs of endogenous phospholipids to study modification of phospholipid distribution in platelet plasma membranes during aging. Asymmetrical distributions and translocation kinetics were very different for spin-labeled phosphatidylserine and spin-labeled phosphatidylcholine in fresh platelet plasma membranes. In freshly prepared platelets and up to day 7, spin-labeled phosphatidylserine very rapidly penetrated to the inner leaflet of the platelet plasma membrane. However, spin-labeled phosphatidylcholine was mainly retained on the external leaflet. From day 7 to day 9, the two translocation kinetics became identical with symmetrical distribution of both spin-labeled phospholipids at equilibrium. Inhibition of translocase activity and modification of membrane stability accounted for these transformations. The rapid re-exposition of spin-labeled phosphatidylserine after stimulation by the calcium ionophore A23187, measured in fresh platelet concentrates, persisted up to day 9 but disappeared between day 10 and day 12. From day 7 to day 9, a strong cytoskeleton proteolysis and marked decrease in intracellular ATP were observed. Moreover, complete suppression of beta-N-acetyl glucosaminidase secretion and vesicle formation after A23187 stimulation of aged platelets indicated that platelets could no longer be activated beyond day 9. Taken together, these results showed that during in vitro aging there are metabolic and membrane modifications in platelet similar to those described for platelet activation. In addition, all of the observed events occurred simultaneously between day 7 and day 9. These results highlight the importance of maintaining plasma membrane asymmetry to increase the hemostatic effectiveness of transfused platelet concentrates.
Gaffet
P
P
URA CNRS 1856, Départment Biologie-Santé, Montpellier, France.
Bassé
F
F
Bienvenüe
A
A
D000118:Acetylglucosaminidase / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism; D001792:Blood Platelets / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D001798:Blood Proteins / Q000032:analysis; D000001:Calcimycin / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D016922:Cellular Senescence; D003598:Cytoskeletal Proteins / Q000032:analysis; D004578:Electron Spin Resonance Spectroscopy; D004591:Electrophoresis, Polyacrylamide Gel; D005994:Glycerophosphates / Q000378:metabolism*; D005997:Glycerylphosphorylcholine / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D008563:Membrane Lipids / Q000032:analysis / Q000378:metabolism*; D010743:Phospholipids / Q000032:analysis / Q000378:metabolism*; D010980:Platelet Membrane Glycoproteins / Q000032:analysis
C088333:1-palmitoyl-2-(4-doxylpentanoyl)-glycerophosphoserine; D001798:Blood Proteins; D003598:Cytoskeletal Proteins; D005994:Glycerophosphates; D008563:Membrane Lipids; D010743:Phospholipids; D010980:Platelet Membrane Glycoproteins; D000001:Calcimycin; D005997:Glycerylphosphorylcholine; C088332:1-palmitoyl-2-(4-doxylpentanoyl)glycerophosphocholine; D000255:Adenosine Triphosphate; D000118:Acetylglucosaminidase